Abeona Therapeutics (ABEO) Registration filing summary
Event summary combining transcript, slides, and related documents.
Registration filing summary
18 Nov, 2026Company overview and business model
Commercial-stage biopharma developing therapies for rare and serious diseases; portfolio includes ZEVASKYN for recessive dystrophic epidermolysis bullosa, ABO-801 for eosinophilic esophagitis (EoE), and investigational T-cell therapy ABO-701.
ZEVASKYN is manufactured in Cleveland and delivered through qualified treatment centers; eight centers were active as of November 2026, with expansion discussions underway.
ABO-801 is a Phase 3-ready, once-daily oral disintegrating fluticasone tablet acquired from Ellodi Pharmaceuticals on November 6, 2026.
Use of proceeds and capital allocation
No proceeds from registered resales will go to the issuer; selling stockholders receive sale proceeds, and issuer-paid registration costs include filing, Nasdaq, legal, and audit fees.
The November 2026 private placement generated approximately $30 million gross; cash exercise of all registered pre-funded warrants would yield approximately $160, with no proceeds from cashless exercise.
Risk factors and disclosures
Investment carries a high degree of risk; forward-looking outcomes include ZEVASKYN commercialization, ABO-801 integration and development, clinical progress and approvals, financing needs, equity dilution, and IP protection.
Forward-looking statements are subject to risks, uncertainties, and assumptions; actual results may differ materially, and statements speak only as of their respective dates.
Latest events from Abeona Therapeutics
- ZEVASKYN launch ramp leads, with ABO-801 and partnered-program catalysts ahead.ABEO
Jefferies Global Healthcare Conference - ABO-801 adds a redesigned EoE Phase III program alongside ZEVASKYN’s expanding launch.ABEO
Stifel 2026 Healthcare Conference 2026 - Strong histologic results; exploratory DSQ mapping informs symptom endpoint strategy.ABEO
Clinical Development History presentation - ZEVASKYN’s $11.4M Q2 revenue anchors a broader cell- and gene-therapy pipeline.ABEO
Corporate presentation - ZEVASKYN revenue rose 18% QoQ as ABO-801 advanced toward Phase III.ABEO
Q3 2026 - ZEVASKYN launch accelerates with rising revenue, broad access, and a robust pipeline of gene therapies.ABEO
H.C. Wainwright 28th Annual Global Investment Conference - Durable gene therapy launch advances with expanding treatment centers and strong patient access.ABEO
Morgan Stanley 24th Annual Global Healthcare Conference - Steady ZEVASKYN rollout, robust coverage, and pipeline advances set stage for strong future growth.ABEO
12th Annual Cantor Fitzgerald Global Healthcare Conference - Q2 2026 ZEVASKYN revenue up 31% to $11.4M, NTAP status secured, net loss $20.2M, cash $146.8M.ABEO
Q2 2026